Intention to Participate in a COVID-19 Vaccine Clinical Trial and to Get Vaccinated Against COVID-19 in France During the Pandemic

Overview

Journal Vaccine

Specialty Allergy & Immunology

Date 2020 Sep 29

PMID 32988688

Citations 363

Authors

Maelle Detoc

Sebastien Bruel

Paul Frappe

Bernard Tardy

Elisabeth Botelho-Nevers

Amandine Gagneux-Brunon

Affiliations

Soon will be listed here.

Abstract

Introduction: The world is facing the COVID-19 pandemic. The development of a vaccine is challenging. We aimed to determine the proportion of people who intend to get vaccinated against COVID-19 in France or to participate in a vaccine clinical trial.

Methods: We conducted an anonymous on-line survey from the 26th of March to the 20th of April 2020. Primary endpoints were the intention to get vaccinated against COVID-19 if a vaccine was available or participate in a vaccine clinical trial.

Results: Three thousand two hundred and fifty nine individuals answered the survey; women accounted for 67.4% of the respondents. According to their statements, 2.512 participants (77.6%, 95% CI 76.2-79%) will certainly or probably agree to get vaccinated against COVID-19. Older age, male gender, fear about COVID-19, being a healthcare worker and individual perceived risk were associated with COVID-19 vaccine acceptance. Vaccine hesitancy was associated with a decrease in COVID-19 vaccine acceptance. One thousand and five hundred and fifty respondents (47.6% 95% CI 45.9-49.3%) will certainly or probably agree to participate in a COVID-19 vaccine clinical trial. Older age, male gender, being a healthcare worker and individual perceived risk were associated with potential acceptance to participate in a COVID-19 vaccine clinical trial. Vaccine hesitancy was associated with refusal for participation in a COVID-19 vaccine clinical trial.

Conclusions: Nearly 75% and 48% of the survey respondents were respectively likely to accept vaccination or participation in a clinical trial against COVID-19. Vaccine hesitancy will be the major barrier to COVID-19 vaccine uptake.

Citing Articles

Perceived social support and self-stigma as factors of COVID-19 booster vaccination behavior and intention via cognitive coping and emotion regulation among people infected with COVID-19 in Hong Kong.

Zhang X, Luan Y, Tang Y, Lau M, Yu Y, Gu J BMC Public Health. 2025; 25(1):659.

PMID: 39966881 PMC: 11834225. DOI: 10.1186/s12889-025-21899-x.

Factors that influence recruitment to COVID-19 vaccine trials: a qualitative evidence synthesis.

Biesty L, Sheehan S, Meskell P, Dowling M, Glenton C, Shepperd S Trials. 2024; 25(1):837.

PMID: 39696633 PMC: 11657826. DOI: 10.1186/s13063-024-08670-0.

[Evaluation of the scenario of hesitancy in vaccines against seasonal influenza among public school teachers in Teresina, Piauí State, Brazil, in COVID-19 times].

Pierote B, Suarez-Mutis M, Werneck G Cad Saude Publica. 2024; 40(10):e00167823.

PMID: 39607144 PMC: 11654113. DOI: 10.1590/0102-311XPT167823.

Knowledge and perception of a clinical trial among the participants: An experience from oral cholera vaccine study in Koshi Province, Nepal.

Chaudhary S, Uranw S, Rai B, Keshary Bhatta N, Shah G, Poudel P Hum Vaccin Immunother. 2024; 20(1):2416760.

PMID: 39410717 PMC: 11485811. DOI: 10.1080/21645515.2024.2416760.

Attitudes and intentions of parents towards the COVID-19 vaccine for their children at a special moment of the pandemic.

Celik Odabasi N, Tayhan A, Mermer G PeerJ. 2024; 12:e18056.

PMID: 39346061 PMC: 11438426. DOI: 10.7717/peerj.18056.

References

Lurie N, Saville M, Hatchett R, Halton J . Developing Covid-19 Vaccines at Pandemic Speed. N Engl J Med. 2020; 382(21):1969-1973. DOI: 10.1056/NEJMp2005630. View

Schaffer DeRoo S, Pudalov N, Fu L . Planning for a COVID-19 Vaccination Program. JAMA. 2020; 323(24):2458-2459. DOI: 10.1001/jama.2020.8711. View

Killian M, Detoc M, Berthelot P, Charles R, Gagneux-Brunon A, Lucht F . Vaccine hesitancy among general practitioners: evaluation and comparison of their immunisation practice for themselves, their patients and their children. Eur J Clin Microbiol Infect Dis. 2016; 35(11):1837-1843. DOI: 10.1007/s10096-016-2735-4. View

Chirico F, Nucera G, Magnavita N . COVID-19: Protecting Healthcare Workers is a priority. Infect Control Hosp Epidemiol. 2020; 41(9):1117. PMC: 7198459. DOI: 10.1017/ice.2020.148. View

Eyal N, Lipsitch M, Smith P . Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure. J Infect Dis. 2020; 221(11):1752-1756. PMC: 7184325. DOI: 10.1093/infdis/jiaa152. View

Agrinier N, Le Marechal M, Fressard L, Verger P, Pulcini C . Discrepancies between general practitioners' vaccination recommendations for their patients and practices for their children. Clin Microbiol Infect. 2016; 23(5):311-317. DOI: 10.1016/j.cmi.2016.08.019. View

John T, Samuel R . Herd immunity and herd effect: new insights and definitions. Eur J Epidemiol. 2000; 16(7):601-6. DOI: 10.1023/a:1007626510002. View

Cobb E, Singer D, Davis M . Public interest in medical research participation: differences by volunteer status and study type. Clin Transl Sci. 2014; 7(2):145-9. PMC: 4012324. DOI: 10.1111/cts.12142. View

Larson H, de Figueiredo A, Xiahong Z, Schulz W, Verger P, Johnston I . The State of Vaccine Confidence 2016: Global Insights Through a 67-Country Survey. EBioMedicine. 2016; 12:295-301. PMC: 5078590. DOI: 10.1016/j.ebiom.2016.08.042. View

10.

Guthmann J, Fonteneau L, Bonmarin I, Levy-Bruhl D . Influenza vaccination coverage one year after the A(H1N1) influenza pandemic, France, 2010-2011. Vaccine. 2011; 30(6):995-7. DOI: 10.1016/j.vaccine.2011.12.011. View

11.

Maltezou H, Dedoukou X, Tseroni M, Tsonou P, Raftopoulos V, Papadima K . SARS-CoV-2 Infection in Healthcare Personnel With High-risk Occupational Exposure: Evaluation of 7-Day Exclusion From Work Policy. Clin Infect Dis. 2020; 71(12):3182-3187. PMC: 7337654. DOI: 10.1093/cid/ciaa888. View

12.

Determann D, de Bekker-Grob E, French J, Voeten H, Richardus J, Das E . Future pandemics and vaccination: Public opinion and attitudes across three European countries. Vaccine. 2016; 34(6):803-8. DOI: 10.1016/j.vaccine.2015.12.035. View

13.

Ahmed N, Quinn S, Hancock G, Freimuth V, Jamison A . Social media use and influenza vaccine uptake among White and African American adults. Vaccine. 2018; 36(49):7556-7561. PMC: 10655625. DOI: 10.1016/j.vaccine.2018.10.049. View

14.

Le T, Andreadakis Z, Kumar A, Roman R, Tollefsen S, Saville M . The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020; 19(5):305-306. DOI: 10.1038/d41573-020-00073-5. View

15.

Detoc M, Launay O, Duale C, Mutter C, Le Huec J, Lenzi N . Barriers and motivations for participation in preventive vaccine clinical trials: Experience of 5 clinical research sites. Vaccine. 2019; 37(44):6633-6639. DOI: 10.1016/j.vaccine.2019.09.048. View

16.

Torreele E . The rush to create a covid-19 vaccine may do more harm than good. BMJ. 2020; 370:m3209. DOI: 10.1136/bmj.m3209. View

17.

Wilson R, Zaytseva A, Bocquier A, Nokri A, Fressard L, Chamboredon P . Vaccine hesitancy and self-vaccination behaviors among nurses in southeastern France. Vaccine. 2019; 38(5):1144-1151. DOI: 10.1016/j.vaccine.2019.11.018. View

18.

Rey D, Fressard L, Cortaredona S, Bocquier A, Gautier A, Peretti-Watel P . Vaccine hesitancy in the French population in 2016, and its association with vaccine uptake and perceived vaccine risk-benefit balance. Euro Surveill. 2018; 23(17). PMC: 5930729. DOI: 10.2807/1560-7917.ES.2018.23.17.17-00816. View

19.

Neumann-Bohme S, Varghese N, Sabat I, Pita Barros P, Brouwer W, van Exel J . Once we have it, will we use it? A European survey on willingness to be vaccinated against COVID-19. Eur J Health Econ. 2020; 21(7):977-982. PMC: 7317261. DOI: 10.1007/s10198-020-01208-6. View